𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Head and neck cancer : Proteomic advances and biomarker achievements

✍ Scribed by Taia Maria Berto Rezende; Mirna de Souza Freire; Octávio Luiz Franco

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
201 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proteomic identification of serum biomar
Proteomic identification of serum biomarkers for head and neck cancer surveillance
✍ Christine G. Gourin; Wenbo Zhi; Bao-Ling Adam 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract ## Objectives/Hypothesis: Serum protein profiling by SELDI‐TOF‐MS distinguishes pretreatment and post‐treatment samples from patients with head and neck squamous cell cancer (HNSCC) by disease status (disease‐free or recurrence) with a high degree of sensitivity and specificity. We sou

Mass spectrometry-based clinical proteom
Mass spectrometry-based clinical proteomics: Head-and-neck cancer biomarkers and drug-targets discovery
✍ Ajay Matta; Ranju Ralhan; Leroi V. DeSouza; K.W. Michael Siu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB

## Abstract Mass spectrometry (MS)‐based proteomics is a rapidly developing technology for both qualitative and quantitative analyses of proteins, and investigations into protein posttranslational modifications, subcellular localization, and interactions. Recent advancements in MS have made tremend

Treatment of advanced cancer of the head
Treatment of advanced cancer of the head and neck
✍ Fred J. Ansfield; Guillermo Ramirez; Hugh L. Davis Jr.; Bernard C. Korbitz; Halv 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 2 views
Preoperative chemo-radiotherapy in advan
Preoperative chemo-radiotherapy in advanced head and neck cancer
✍ Pearlman, Nathan W. ;Meyers, Arlen D. ;Johnson, F. Bing ;Dibella, Nicholas J. 📂 Article 📅 1982 🏛 Wiley (John Wiley & Sons) ⚖ 451 KB 👁 1 views

## Abstract In a prospective evaluation, two preoperative courses of methotrexate, bleomycin, and cisplatin combined with 2,000 rad/10 fractions (“chemo‐radiotherapy”) yielded 78% response rates in previously untreated advanced head and neck cancer. Similarly staged patients receiving preoperative